Test-mix 350 350mg/ml 10ml Vial by Master Pharma

Usage

1. Remove the vial from its storage location (15–25 °C, dark) and allow it to reach room temperature if it has been kept in a cool area — warmer oil flows more smoothly through the needle.
2. Inspect the vial contents visually against a light background; the oil should be clear and free of particulate matter, cloudiness, or abnormal colour before proceeding.
3. Wipe the rubber septum thoroughly with a fresh 70 % isopropyl alcohol swab and allow it to dry completely before needle insertion.
4. Draw the required volume using a fresh 21 G or 23 G needle; invert the vial and withdraw slowly to avoid introducing air bubbles that can displace oil and distort the drawn volume.
5. Switch to a fresh injection needle before administering — the draw needle may have picked up traces of septum rubber — then inject into the target muscle using standard intramuscular technique.
6. Return the vial immediately to its designated storage position (upright, dark, 15–25 °C); never leave it in a car glovebox, windowsill, or bathroom cabinet where temperature and humidity fluctuate.

Warnings

Frequently asked questions

What is the correct storage temperature for Master Pharma Test-mix 350 and why does it matter for a four-ester blend?

Store Test-mix 350 between 15 °C and 25 °C in a dark, dry location. A four-ester blend is more sensitive to thermal degradation than a single-ester product because heat-driven ester hydrolysis can affect each fraction at a different rate, selectively distorting the pharmacokinetic release profile. Keeping the vial within the validated temperature band ensures all four ester fractions remain at their declared proportions through the stated shelf life.

What happens to Test-mix 350 if it is accidentally exposed to temperatures above 30 °C?

Sustained exposure above 30 °C accelerates hydrolytic degradation of the ester bonds in the oil phase, progressively reducing active testosterone ester content below the 350 mg/ml label claim. The propionate fraction, carrying the shortest carbon chain, is typically the first affected. Vials that have experienced prolonged heat excursion should be visually inspected for cloudiness, precipitate, or colour change and discarded if any abnormality is observed.

Should Test-mix 350 be refrigerated after opening the 10 ml vial?

Refrigeration is not required and is not recommended as the primary storage method. Repeated cooling and warming of an oil-based injectable can cause the vehicle to become transiently viscous, making accurate draw volumes difficult. Store the opened vial at room temperature (15–25 °C), away from light, and ensure the septum is disinfected before each draw to maintain microbiological integrity across the multiple injection events a 10 ml vial supports.

How many injections can I draw from a single 10 ml vial of Test-mix 350, and how does this affect sterility over time?

At 350 mg/ml a 10 ml vial contains 3,500 mg total. A common twice-weekly protocol at 350–700 mg/week yields between 10 and 20 individual draws. Each septum puncture carries a cumulative contamination risk; use a fresh 21–23 G needle for every draw, wipe the septum with 70 % isopropyl alcohol each time, and discard the vial if any visual change — cloudiness, particulate matter, or discolouration — appears before the contents are exhausted.

Does freezing affect the quality or concentration of Test-mix 350?

Freezing an oil-based testosterone injectable can disrupt vehicle homogeneity and cause the active ester blend to crystallise unevenly within the carrier oil. Upon thawing, the four ester fractions may not redistribute uniformly, meaning individual draws could contain off-proportion ester ratios. If a vial has been accidentally frozen, do not attempt to redissolve by overheating; the safest course is to discard the affected vial and replace it with a unit stored under validated conditions. (2) angle_used

Manufacturer

For the Test-mix 350 SKU, Master Pharma's quality release sequence is structured around two compound-specific analytical requirements that operate independently of each other and must both return compliant results before a batch is authorised for distribution. The first gate is reversed-phase HPLC potency and proportion verification: the chromatographic run quantifies not only total testosterone ester content against the 350 mg/ml label claim but also confirms that each of the four constituent ester fractions is present in its intended proportional contribution — a distinction that separates fraction-aware release testing from bulk-concentration-only approaches. The second gate is LAL (Limulus Amebocyte Lysate) endotoxin quantification on the finished product, with the measured EU/ml result evaluated against injectable parenteral safety thresholds specified for the route of administration. Both gate outcomes are recorded on the lot Certificate of Analysis, which accompanies the batch through the supply chain and is available as the primary traceability document for the product.